Pericarditis https://greenmedinfo.com/taxonomy/term/3829/all en Study results indicate that a higher incidence of myocarditis or pericarditis was found after COVID-19 vaccination. https://greenmedinfo.com/article/study-results-indicate-higher-incidence-myocarditis-or-pericarditis-was-found- PMID:  Am J Prev Med. 2022 Sep 26. Epub 2022 Sep 26. PMID: 36266115 Abstract Title:  A Systematic Review and Meta-analysis of the Association Between SARS-CoV-2 Vaccination and Myocarditis or Pericarditis. Abstract:  INTRODUCTION: There have been reports of potential negative cardiovascular effects from the COVID-19 vaccine, such as myocarditis or pericarditis. This study sought to ascertain the risk of myocarditis/pericarditis after COVID-19 vaccination by conducting an extensive meta-analysis of published cases.METHODS: A systematic literature search was conducted in 7 online databases by March 31, 2022. Heterogeneity was tested by Iindex. RR and 95% CI were pooled through either random-effect or fixed-effect models. Sensitivity analysis and publication bias were also conducted.RESULTS: A total of 11 studies with 58,620,611 subjects were included. COVID-19 vaccination correlated with an increased risk of myocarditis or pericarditis (RR=2.04; 95% CI=1.33, 3.14). In addition, an increased risk of myocarditis or pericarditis in people who received the second dose of COVID-19 vaccine compared with that in those who received only the first dose of COVID-19 vaccine was also found (RR=4.06; 95% CI=2.08, 7.92). An increased incidence of pericarditis or myocarditis was noted predominantly in those who received BNT162b2 and mRNA-1273 vaccines (RR=2.19; 95% CI=1.46, 3.29 and RR=4.15; 95% CI=1.87, 9.22, respectively).DISCUSSION: Study results indicate that a higher incidence of myocarditis or pericarditis was found after COVID-19 vaccination. In addition, the risk of developing myocarditis or pericarditis was greater after the second dose than after the first dose. Nevertheless, the risks of myocarditis and pericarditis in COVID-19 vaccine recipients are still significantly lower than the health risks observed in patients with COVID-19. Therefore, the benefits and harms must be carefully assessed to determine the best management option for patients who are in the high-risk group of myocarditis or pericarditis. <p><a href="https://greenmedinfo.com/article/study-results-indicate-higher-incidence-myocarditis-or-pericarditis-was-found-" target="_blank">read more</a></p> https://greenmedinfo.com/article/study-results-indicate-higher-incidence-myocarditis-or-pericarditis-was-found-#comments Myocarditis Pericarditis Vaccine-induced Toxicity Cardiotoxic Vaccination: COVID-19 Increased Risk Meta Analysis Review Wed, 09 Nov 2022 00:05:47 +0000 greenmedinfo 266169 at https://greenmedinfo.com An economic analysis of mass smallpox vaccination reveals that cardiovascular adverse events would be sizeable and costly. https://greenmedinfo.com/article/economic-analysis-mass-smallpox-vaccination-reveals-cardiovascular-adverse-eve PMID:  J Rheumatol. 1994 Jul;21(7):1305-9. PMID: 18284356 Abstract Title:  Economics of cardiac adverse events after smallpox vaccination: lessons from the 2003 US Vaccination Program. Abstract:  Of&gt;39,000 civilian public health responders vaccinated against smallpox in 2003, 203 reported cardiovascular adverse events (CAEs). An association exists between the US vaccinia strain and myocarditis and/or pericarditis (&quot;myo/pericarditis&quot; [MP]). Other associations are inconclusive. We used surveillance and follow-up survey data of CAE case patients to estimate the resources used during the 2003 smallpox vaccination program and used a probabilistic model to estimate the potential costs of CAEs in a mass vaccination campaign. For every million adult vaccinees, 3001 CAEs (including 351 MP cases) would occur, with&gt;92% in revaccinees. CAEs would require a median of 5934 outpatient visits, 1786 emergency department visits, 533 days in general wards, 132 days in intensive care units, 5484 cardiac enzymes tests, 3504 electrocardiograms, 3049 chemistry tests, 2828 complete blood counts, and 1444 transthoracic echocardiograms, among other procedures. CAEs would reduce productivity (15,969 work days lost) and cost $11 per vaccinee. In a mass vaccination campaign, the care of a sizable number of CAEs would be resource intensive. https://greenmedinfo.com/article/economic-analysis-mass-smallpox-vaccination-reveals-cardiovascular-adverse-eve#comments Myocarditis Myopericarditis Pericarditis Vaccination: All Vaccination: Smallpox Human Study Sat, 17 Apr 2010 14:28:17 +0000 greenmedinfo 54945 at https://greenmedinfo.com Case report: cytomegalovirus reactivation and pericarditis following ChAdOx1 nCoV-19 vaccination against SARS-CoV-2. https://greenmedinfo.com/article/case-report-cytomegalovirus-reactivation-and-pericarditis-following-chadox1-nc PMID:  Front Immunol. 2021 ;12:784145. Epub 2022 Jan 18. PMID: 35116025 Abstract Title:  Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2. Abstract:  As the coronavirus disease 2019 (COVID-19) pandemic is ongoing and new variants of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are emerging, there is an urgent need for vaccines to protect individuals at high risk for complications and to potentially control disease outbreaks by herd immunity. Surveillance of rare safety issues related to these vaccines is progressing, since more granular data emerge about adverse events of SARS-CoV-2 vaccines during post-marketing surveillance. Varicella zoster virus (VZV), Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivation has already been reported in COVID-19 patients. In addition, adverse events after SARS-CoV-2 mRNA vaccination have also been in the context of varicella zoster virus (VZV) reactivation and directly associated with the mRNA vaccine. We present the first case of CMV reactivation and pericarditis in temporal association with SARS-CoV-2 vaccination, particularly adenovirus-based DNA vector vaccine ChAdOx1 nCoV-19 against SARS-CoV-2. After initiation of antiviral therapy with oral valganciclovir, CMV viremia disappeared and clinical symptoms rapidly improved. Since huge vaccination programs are ongoing worldwide, post-marketing surveillance systems must be in place to assess vaccine safety that is important for the detection of any events. In the context of the hundreds of millions of individuals to be vaccinated against SARS-CoV-2, a potential causal association with CMV reactivation may result in a considerable number of cases with potentially severe complications. <p><a href="https://greenmedinfo.com/article/case-report-cytomegalovirus-reactivation-and-pericarditis-following-chadox1-nc" target="_blank">read more</a></p> https://greenmedinfo.com/article/case-report-cytomegalovirus-reactivation-and-pericarditis-following-chadox1-nc#comments Cytomegalovirus Infections Pericarditis Vaccination: Coronavirus Risk Factors Human: Case Report Sun, 20 Feb 2022 03:52:57 +0000 greenmedinfo 253676 at https://greenmedinfo.com Mesalamine may cause pericarditis. https://greenmedinfo.com/article/mesalamine-may-cause-pericarditis PMID:  Pharmacotherapy. 2002 Mar;22(3):391-4. PMID: 11898896 Abstract Title:  Possible mesalamine-induced pericarditis: case report and literature review. Abstract:  Pericarditis should be considered in any patient complaining of chest pain and/or dyspnea who is taking a product that contains mesalamine or sulfasalazine. A 41-year-old woman was taking mesalamine 800 mg 3 times/day for 3 weeks before hospital admission. She complained of sharp, pleuritic chest pain that radiated down both arms and increased in intensity when lying down. She was diagnosed with pericarditis based on clinical presentation and electrocardiogram findings. Differential diagnoses for myocardial infarction, systemic lupus erythematosus, and viral or bacterial causes were ruled out based on subjective and objective data. Mesalamine-induced pericarditis was considered on hospital day 2, and the drug was discontinued at discharge on day 3. Clinicians should be aware of this potential drug-related complication, as the relationship between mesalamine or sulfasalazine and pericarditis has been reported rarely in the literature. https://greenmedinfo.com/article/mesalamine-may-cause-pericarditis#comments Drug-Induced Toxicity Pericarditis Cardiotoxic Mesalamine Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Human: Case Report Thu, 06 Jan 2011 03:21:17 +0000 greenmedinfo 60128 at https://greenmedinfo.com Myocarditis and pericarditis have been reported following smallpox vaccination in Europe, Australia and the United States. https://greenmedinfo.com/article/myocarditis-and-pericarditis-have-been-reported-following-smallpox-vaccination PMID:  Clin Infect Dis. 2008 Mar 15;46 Suppl 3:S242-50. PMID: 18284365 Abstract Title:  Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States, January-October 2003. Abstract:  Myocarditis was reported after smallpox vaccination in Europe and Australia, but no association had been reported with the US vaccine. We conducted surveillance to describe and determine the frequency of myocarditis and/or pericarditis (myo/pericarditis) among civilians vaccinated during the US smallpox vaccination program between January and October 2003. We developed surveillance case definitions for myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination. We identified 21 myo/pericarditis cases among 37,901 vaccinees (5.5 per 10,000); 18 (86%) were revacinees, 14 (67%) were women, and the median age was 48 years (range, 25-70 years). The median time from vaccination to onset of symptoms was 11 days (range, 2-42 days). Myo/pericarditis severity was mild, with no fatalities, although 9 patients (43%) were hospitalized. Three additional vaccinees were found to have dilated cardiomyopathy, recognized within 3 months after vaccination. We describe an association between smallpox vaccination, using the US vaccinia strain, and myo/pericarditis among civilians. https://greenmedinfo.com/article/myocarditis-and-pericarditis-have-been-reported-following-smallpox-vaccination#comments Myocarditis Myopericarditis Pericarditis Vaccination: All Vaccination: Smallpox Human Study Sat, 17 Apr 2010 14:25:14 +0000 greenmedinfo 54944 at https://greenmedinfo.com Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines. https://greenmedinfo.com/article/myocarditis-and-pericarditis-adolescents-after-first-and-second-doses-mrna-cov PMID:  Eur Heart J Qual Care Clin Outcomes. 2022 03 2 ;8(2):99-103. PMID: 34849667 Abstract Title:  Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines. Abstract:  AIMS: While some concerns about vaccination-related pericarditis and/or myocarditis have been raised, no published data are available on pericarditis and/or myocarditis with mRNA COVID-19 vaccines in the age group of adolescents, particularly 12-15 years. The objective of this study was to determine whether the risk of reporting pericarditis and/or myocarditis with mRNA COVID-19 vaccines varied according to dose of vaccination, age, sex, and type of pericarditis and/or myocarditis in adolescents between 12 and 17 years.METHODS AND RESULTS: We performed an observational study reviewing all reports of adolescents vaccinated with mRNA COVID-19 vaccines and recorded in VigiBase®, the World Health Organization global database of individual case safety reports. We included all reports registered between 1 January 2021 and 14 September 2021. Reporting odds ratios (RORs) with their 95% confidence interval (CI) were calculated to estimate the risk of reporting pericarditis and/or myocarditis. Among 4942 reports with mRNA COVID-19 vaccines in adolescents, we identified 242 pericarditis and/or myocarditis. Compared with the first dose of mRNA COVID-19 vaccines, the second dose was associated with an increased risk of reporting pericarditis and/or myocarditis (ROR 4.95; 95% CI 3.14, 7.89). The risk of reporting pericarditis and/or myocarditis was 10 times higher in boys than in girls and no difference between the two types of vaccines could be demonstrated.CONCLUSION: This investigation including only adolescent data suggests for the first time that the second dose of mRNA COVID-19 vaccines increases the risk of reporting myocarditis/pericarditis compared with the first dose particularly in boys without significant difference between tozinameran and elasomeran. <p><a href="https://greenmedinfo.com/article/myocarditis-and-pericarditis-adolescents-after-first-and-second-doses-mrna-cov" target="_blank">read more</a></p> https://greenmedinfo.com/article/myocarditis-and-pericarditis-adolescents-after-first-and-second-doses-mrna-cov#comments Myocarditis Pericarditis Vaccine-induced Toxicity Cardiotoxic Vaccination: COVID-19 Human: Case Report Sun, 31 Jul 2022 22:05:16 +0000 greenmedinfo 261347 at https://greenmedinfo.com Myopericarditis https://greenmedinfo.com/disease/myopericarditis <div class="field field-image"> <div class="field-items"> <div class="field-item odd"> <img class="imagefield imagefield-field_image" width="450" height="450" alt="" src="//cdn.greenmedinfo.com/sites/default/files/Heart_77.jpg?1482452427" /> </div> </div> </div> <div class="field field-copyright"> <div class="field-items"> <div class="field-item odd"> Copyright: &lt;a href=&#039;http://www.123rf.com/profile_pablofdezr&#039;&gt;pablofdezr / 123RF Stock Photo&lt;/a&gt; </div> </div> </div> <fieldset class="fieldgroup group-facebook-like-info"><legend>Facebook Like Info</legend><div class="field field-facebook-total-count"> <div class="field-items"> <div class="field-item odd"> 0 </div> </div> </div> </fieldset> https://greenmedinfo.com/disease/myopericarditis#comments Myocarditis Pericarditis Sat, 17 Apr 2010 14:08:26 +0000 greenmedinfo 54939 at https://greenmedinfo.com Omega-3 polyunsaturated fatty acids has a preventive effect against atrial fibrillation in a canine model of pericarditis. https://greenmedinfo.com/article/omega-3-polyunsaturated-fatty-acids-has-preventive-effect-against-atrial-fibri PMID:  Heart Rhythm. 2010 Apr;7(4):520-8. Epub 2009 Dec 28. PMID: 20156610 Abstract Title:  n-3 Polyunsaturated fatty acids alter expression of fibrotic and hypertrophic genes in a dog model of atrial cardiomyopathy. Abstract:  BACKGROUND: We previously showed that omega-3 polyunsaturated fatty acids (PUFAs) reduce vulnerability to atrial fibrillation (AF). The mechanisms underlying this effect are unknown.OBJECTIVE: The purpose of this study was to use a genome-wide approach to identify gene expression profiles involved in a new model of AF vulnerability and to determine whether they were altered by PUFA therapy.METHODS: Thirty-six dogs were randomized evenly into three groups. Two groups were paced using simultaneous atrioventricular pacing (SAVP) at 220 bpm for 14 days to induce atrial enlargement, fibrosis, and susceptibility to AF. One group was supplemented with oral PUFAs (850 mg/day) for 21 days, commencing 7 days before the start of pacing (SAVP-PUFAs). The second group received no PUFAs (SAVP-No PUFAs). The remaining dogs were unpaced, unsupplemented controls (CTRL). Atrial tissue was sampled at the end of the protocol. Gene expression was analyzed in four dogs randomly selected from each group (n = 12) via microarray. Results were confirmed with quantitative real-time polymerase chain reaction (RT-PCR) and histology on all 36 dogs.RESULTS: Microarray or quantitative RT-PCR results showed that SAVP-No PUFAs dogs had significantly increased mRNA levels of protein kinase B (Akt), epidermal growth factor (EGF), JAM3, myosin heavy chain alpha (MHCalpha), and CD99 and significantly decreased levels of Smad6 compared with CTRL dogs. Quantitative RT-PCR showed that PUFA supplementation was associated with significant down-regulation of Akt, EGF, JAM3, MHCalpha, and CD99 levels compared with SAVP-No PUFAs dogs.CONCLUSION: The effect of PUFAs on these fibrosis, hypertrophy, and inflammation related genes suggests that, in this model, PUFA-mediated prevention of AF may be due to attenuation of adverse remodeling at the genetic level in response to mechanical stress. https://greenmedinfo.com/article/omega-3-polyunsaturated-fatty-acids-has-preventive-effect-against-atrial-fibri#comments Atrial Fibrillation Omega-3 Fatty Acids Pericarditis Cardiovascular Agents Epidermal growth factor receptor (EGFR) inhibitor JAM3 gene down-regulation Myosin heavy chain alpha (MHCalpha) reducer Protein Kinase Inhibitors Animal Study Fri, 20 May 2011 19:05:16 +0000 greenmedinfo 64114 at https://greenmedinfo.com Passive surveillance significantly underestimates the true incidence of myocarditis/pericarditis after smallpox immunization. https://greenmedinfo.com/article/passive-surveillance-significantly-underestimates-true-incidence-myocarditispe PMID:  PLoS One. 2015 ;10(3):e0118283. Epub 2015 Mar 20. PMID: 25793705 Abstract Title:  A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination. Abstract:  BACKGROUND: Although myocarditis/pericarditis (MP) has been identified as an adverse event following smallpox vaccine (SPX), the prospective incidence of this reaction and new onset cardiac symptoms, including possible subclinical injury, has not been prospectively defined.PURPOSE: The study&#039;s primary objective was to determine the prospective incidence of new onset cardiac symptoms, clinical and possible subclinical MP in temporal association with immunization.METHODS: New onset cardiac symptoms, clinical MP and cardiac specific troponin T (cTnT) elevations following SPX (above individual baseline values) were measured in a multi-center prospective, active surveillance cohort study of healthy subjects receiving either smallpox vaccine or trivalent influenza vaccine (TIV).RESULTS: New onset chest pain, dyspnea, and/or palpitations occurred in 10.6% of SPX-vaccinees and 2.6% of TIV-vaccinees within 30 days of immunization (relative risk (RR) 4.0, 95% CI: 1.7-9.3). Among the 1081 SPX-vaccinees with complete follow-up, 4 Caucasian males were diagnosed with probable myocarditis and 1 female with suspected pericarditis. This indicates a post-SPX incidence rate more than 200-times higher than the pre-SPX background population surveillance rate of myocarditis/pericarditis (RR 214, 95% CI 65-558). Additionally, 31 SPX-vaccinees without specific cardiac symptoms were found to have over 2-fold increases in cTnT (&gt;99th percentile) from baseline (pre-SPX) during the window of risk for clinical myocarditis/pericarditis and meeting a proposed case definition for possible subclinical myocarditis. This rate is 60-times higher than the incidence rate of overt clinical cases. No clinical or possible subclinical myocarditis cases were identified in the TIV-vaccinated group.CONCLUSIONS: Passive surveillance significantly underestimates the true incidence of myocarditis/pericarditis after smallpox immunization. Evidence of subclinical transient cardiac muscle injury post-vaccinia immunization is a finding that requires further study to include long-term outcomes surveillance. Active safety surveillance is needed to identify adverse events that are not well understood or previously recognized. <p><a href="https://greenmedinfo.com/article/passive-surveillance-significantly-underestimates-true-incidence-myocarditispe" target="_blank">read more</a></p> https://greenmedinfo.com/article/passive-surveillance-significantly-underestimates-true-incidence-myocarditispe#comments Myocarditis Pericarditis Vaccine-induced Toxicity Vaccination: Influenza Vaccination: Smallpox Human Study Thu, 09 Feb 2023 05:24:41 +0000 greenmedinfo 270802 at https://greenmedinfo.com Smallpox vaccination has been associated with cardiac complications such as myopericarditis. https://greenmedinfo.com/article/smallpox-vaccination-has-been-associated-cardiac-complications-such-myopericar PMID:  South Med J. 2009 May 7. Epub 2009 May 7. PMID: 19434043 Abstract Title:  Cardiac complications after smallpox vaccination. Abstract:  In 2002, the US Federal government initiated a campaign to vaccinate military personnel and members of the civilian population against smallpox to counter a possible bioterrorism attack. More than 1,200,000 military personnel and approximately 40,000 civilians have been vaccinated since that time. The incidence of myopericarditis in these vaccinees has clearly exceeded calculated background rates and has prompted discussion about cardiac inflammation and other potential vaccine-associated cardiac complications such as dilated cardiomyopathy (DCM) and myocardial ischemia. Although it seems reasonable to predict that some cases of smallpox-associated myopericarditis will progress to DCM, only small numbers have been documented so far, and a causal relationship is difficult to ascertain. With regard to myocardial ischemia, both historical and current data do not suggest a causal association with the vaccine. We describe a case report of myopericarditis following smallpox immunization and provide a review of all cardiac complications associated with vaccination. https://greenmedinfo.com/article/smallpox-vaccination-has-been-associated-cardiac-complications-such-myopericar#comments Myocarditis Myopericarditis Pericarditis Vaccination: All Vaccination: Smallpox Human Study Sat, 17 Apr 2010 14:08:50 +0000 greenmedinfo 54941 at https://greenmedinfo.com These results did not observe an increased incidence of neither pericarditis nor myocarditis in adult patients recovering from COVID-19 infection. https://greenmedinfo.com/article/these-results-did-not-observe-increased-incidence-neither-pericarditis-nor-myo PMID:  J Clin Med. 2022 Apr 15 ;11(8). Epub 2022 Apr 15. PMID: 35456309 Abstract Title:  The Incidence of Myocarditis and Pericarditis in Post COVID-19 Unvaccinated Patients-A Large Population-Based Study. Abstract:  Myocarditis and pericarditis are potential post-acute cardiac sequelae of COVID-19 infection, arising from adaptive immune responses. We aimed to study the incidence of post-acute COVID-19 myocarditis and pericarditis. Retrospective cohort study of 196,992 adults after COVID-19 infection in Clalit Health Services members in Israel between March 2020 and January 2021. Inpatient myocarditis and pericarditis diagnoses were retrieved from day 10 after positive PCR. Follow-up was censored on 28 February 2021, with minimum observation of 18 days. The control cohort of 590,976 adults with at least one negative PCR and no positive PCR were age- and sex-matched. Since the Israeli vaccination program was initiated on 20 December 2020, the time-period matching of the control cohort was calculated backward from 15 December 2020. Nine post-COVID-19 patients developed myocarditis (0.0046%), and eleven patients were diagnosed with pericarditis (0.0056%). In the control cohort, 27 patients had myocarditis (0.0046%) and 52 had pericarditis (0.0088%). Age (adjusted hazard ratio [aHR] 0.96, 95% confidence interval [CI]; 0.93 to 1.00) and male sex (aHR 4.42; 95% CI, 1.64 to 11.96) were associated with myocarditis. Male sex (aHR 1.93; 95% CI 1.09 to 3.41) and peripheral vascular disease (aHR 4.20; 95% CI 1.50 to 11.72) were associated with pericarditis. Post COVID-19 infection was not associated with either myocarditis (aHR 1.08; 95% CI 0.45 to 2.56) or pericarditis (aHR 0.53; 95% CI 0.25 to 1.13). We did not observe an increased incidence of neither pericarditis nor myocarditis in adult patients recovering from COVID-19 infection. <p><a href="https://greenmedinfo.com/article/these-results-did-not-observe-increased-incidence-neither-pericarditis-nor-myo" target="_blank">read more</a></p> https://greenmedinfo.com/article/these-results-did-not-observe-increased-incidence-neither-pericarditis-nor-myo#comments Myocarditis Pericarditis Vaccination: Coronavirus Vaccination: COVID-19 Increased Risk Human Study Tue, 08 Nov 2022 22:34:07 +0000 greenmedinfo 266164 at https://greenmedinfo.com This population-based study of about 3 millions of residents in Italy suggested that mRNA vaccines were associated with myocarditis/pericarditis. https://greenmedinfo.com/article/population-based-study-about-3-millions-residents-italy-suggested-mrna-vaccine PMID:  PLoS Med. 2022 07 ;19(7):e1004056. Epub 2022 Jul 28. PMID: 35900992 Abstract Title:  Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study. Abstract:  BACKGROUND: Myocarditis and pericarditis following the Coronavirus Disease 2019 (COVID-19) mRNA vaccines administration have been reported, but their frequency is still uncertain in the younger population. This study investigated the association between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA vaccines, BNT162b2, and mRNA-1273 and myocarditis/pericarditis in the population of vaccinated persons aged 12 to 39 years in Italy.METHODS AND FINDINGS: We conducted a self-controlled case series study (SCCS) using national data on COVID-19 vaccination linked to emergency care/hospital discharge databases. The outcome was the first diagnosis of myocarditis/pericarditis between 27 December 2020 and 30 September 2021. Exposure risk period (0 to 21 days from the vaccination day, subdivided in 3 equal intervals) for first and second dose was compared with baseline period. The SCCS model, adapted to event-dependent exposures, was fitted using unbiased estimating equations to estimate relative incidences (RIs) and excess of cases (EC) per 100,000 vaccinated by dose, age, sex, and vaccine product. Calendar period was included as time-varying confounder in the model. During the study period 2,861,809 persons aged 12 to 39 years received mRNA vaccines (2,405,759 BNT162b2; 456,050 mRNA-1273); 441 participants developed myocarditis/pericarditis (346 BNT162b2; 95 mRNA-1273). Within the 21-day risk interval, 114 myocarditis/pericarditis events occurred, the RI was 1.99 (1.30 to 3.05) after second dose of BNT162b2 and 2.22 (1.00 to 4.91) and 2.63 (1.21 to 5.71) after first and second dose of mRNA-1273. During the [0 to 7) days risk period, an increased risk of myocarditis/pericarditis was observed after first dose of mRNA-1273, with RI of 6.55 (2.73 to 15.72), and after second dose of BNT162b2 and mRNA-1273, with RIs of 3.39 (2.02 to 5.68) and 7.59 (3.26 to 17.65). The number of EC for second dose of mRNA-1273 was 5.5 per 100,000 vaccinated (3.0 to 7.9). The highest risk was observed in males, at [0 to 7) days after first and second dose of mRNA-1273 with RI of 12.28 (4.09 to 36.83) and RI of 11.91 (3.88 to 36.53); the number of EC after the second dose of mRNA-1273 was 8.8 (4.9 to 12.9). Among those aged 12 to 17 years, the RI was of 5.74 (1.52 to 21.72) after second dose of BNT162b2; for this age group, the number of events was insufficient for estimating RIs after mRNA-1273. Among those aged 18 to 29 years, the RIs were 7.58 (2.62 to 21.94) after first dose of mRNA-1273 and 4.02 (1.81 to 8.91) and 9.58 (3.32 to 27.58) after second dose of BNT162b2 and mRNA-1273; the numbers of EC were 3.4 (1.1 to 6.0) and 8.6 (4.4 to 12.6) after first and second dose of mRNA-1273. The main study limitations were that the outcome was not validated through review of clinical records, and there was an absence of information on the length of hospitalization and, thus, the severity of the outcome.CONCLUSIONS: This population-based study of about 3 millions of residents in Italy suggested that mRNA vaccines were associated with myocarditis/pericarditis in the population younger than 40 years. According to our results, increased risk of myocarditis/pericarditis was associated with the second dose of BNT162b2 and both doses of mRNA-1273. The highest risks were observed in males of 12 to 39 years and in males and females 18 to 29 years vaccinated with mRNA-1273. The public health implication of these findings should be considered in the light of the proven mRNA vaccine effectiveness in preventing serious COVID-19 disease and death. <p><a href="https://greenmedinfo.com/article/population-based-study-about-3-millions-residents-italy-suggested-mrna-vaccine" target="_blank">read more</a></p> https://greenmedinfo.com/article/population-based-study-about-3-millions-residents-italy-suggested-mrna-vaccine#comments Myocarditis Pericarditis Vaccine-induced Toxicity Vaccination: COVID-19 Increased Risk Human Study Tue, 08 Nov 2022 23:49:13 +0000 greenmedinfo 266167 at https://greenmedinfo.com Vaccine Failure Skyrockets To Over 6 Million! https://greenmedinfo.com/blog/vaccine-failure-skyrockets-over-6-million <p class="rtecenter"><img alt="" src="//cdn.greenmedinfo.com/sites/default/files/ckeditor/blank.justin/images/Vaccine_Failure_Skyrockets_To_Over_6_Million-GreenMedInfo.jpg" /><br /> <span style="font-size:12px;"><strong>Originally published on <a href="https://www.americaoutloud.com/this-week-in-covid-vaccine-failure-skyrockets-to-over-6-million/" rel="dofollow" target="_blank">www.americaoutloud.com</a></strong></span></p> <p><span style="font-size:18px;"><strong><span style="letter-spacing: 0px;">In This Edition</span></strong></span></p><p><a href="https://greenmedinfo.com/blog/vaccine-failure-skyrockets-over-6-million" target="_blank">read more</a></p> https://greenmedinfo.com/blog/vaccine-failure-skyrockets-over-6-million#comments Coronavirus Disease Coronavirus Infection Myocarditis Pericarditis Vaccination: All Chemical and Drug Toxicity Health Guide: Chemical Exposures Health Guide: Corruption in Science Health Guide: Viruses Vaccine Effects Vaccine Rights corruption in science mass vaccination viral infections Mon, 31 Jan 2022 23:34:37 +0000 DrHenryEaly 252595 at https://greenmedinfo.com